Protagen awarded GMP certification

29 April 2007

Germany's Protagen AG has been awarded Good Manufacturing Practice certification and will be providing customers with protein analysis services in accordance with international quality assurance guidelines with immediate effect.

The firm says it is one of the first biotechnology companies in Germany to meet the requirements for approval from the US Food and Drug Administration and the European Medicines Agency (EMEA) to offer analytical methods within the guidelines for manufacturers of therapeutic proteins.

Commenting on the news, Protagen chief executive Christoph Huels said: "being awarded GMP certification is a great achievement for Protagen and underlines our strategy to provide protein analysis services of the highest quality. We are committed to supporting our customers in their effort to meet the industry's increasingly strict controls and regulations, and we are delighted to be able to offer the flexibility of tailoring research programs and providing protein services under GMP where required."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight